$エテルナ セラピューティクス(ERNA.US)$ NEWS Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory Diseases
Peter Cicala's appointment to Eterna's Board is viewed positively due to his extensive biotech and pharma industry experience. His intellectual property expertise and strategic management skills are anticipated to aid in developing next-gen mRNA cell engineering therapies.
The appointment of Dr. Bristol for Eterna Therapeutics is positive due to his vast experience in drug discovery. His track record could drive the company's strategic direction.
エテルナ セラピューティクスに関するコメント
NEWS
Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory Diseases
まだコメントはありません